IMVT
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Immunovant, Inc. is a clinical-stage immunology company developing therapies for IgG-mediated autoimmune diseases. Its lead product candidate, imeroprubart (IMVT-1402), is a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor (FcRn) to reduce pathogenic immunoglobulin G (IgG) levels. The company is advancing IMVT-1402 in clinical trials for indications including Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, and cutaneous lupus erythematosus. Immunovant previously developed batoclimab, a first-generation anti-FcRn antibody, but discontinued its development to focus resources on IMVT-1402. The company collaborates with HanAll on antibody design and utilizes the YpsoMate autoinjector developed by Ypsomed AG for drug delivery. Its therapeutic areas span endocrinology, neurology, rheumatology, and dermatology.

Summarised from the company's own disclosures, fiscal year ended May 2026

Industry Biotechnology Homepage immunovant.com
Sector Healthcare IR page immunovant.com/investors
Tags
immunology, autoimmune diseases, fcrn inhibitors, monoclonal antibodies, graves' disease, myasthenia gravis, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus, subcutaneous injection, imeroprubart, IMVT-1402, batoclimab, YpsoMate, HanAll, Ypsomed AG
Press page immunovant.com/investors/news-events/press-releases

Metrics

Valuation  
Market cap $ 7.444B
Market cap (USD) $ 7.444B
P/E -14.12
PEG —
P/BV 11.33
P/S —
P/OCF -18.85
P/FCF -18.28
Dividend yield —
Turnover / mcap —
Returns  
ROE -64.8%
ROI -59.3%
ROIC -46.9%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 12
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 957.014M 776.222M 666.365M 405.838M 515.564M 412.489M 109.387M 13.828M
Net profit -505.606M -413.84M -259.336M -210.96M -156.73M -107.431M -66.388M -28.599M
Free cash flow -407.318M -376.633M -214.587M -188.39M -106.366M -83.537M -53.388M -28.599M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 24.84 17.09 32.31 15.51 5.51 16.04 15.56 —
Price performance 12m 0.45 -0.47 1.08 1.81 -0.66 0.03 — —

Filed figures

Figure Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (USD) — — 596,000 12.2M 700,000 5.34M 2.08M 1.13M
↳ YoY growth +1,951.8% -94.3% +662.4% -61.0% -45.6%
↳ 5y CAGR +13.7%
Lease liabilities (USD) — 0.00 3.42M 2.36M 1.22M 138,000 98,000 72,000
Cash and deposits (USD) 147,800 101M 400M 494M 377M 635M 714M 902M
Right-of-use assets (USD) — 0.00 3.28M 2.3M 1.17M 133,000 98,000 72,000
Cash flow detail
Operating cash flow (USD) -28.5M -53.4M -83.3M -106M -188M -214M -376M -407M
Purchases of property, plant and equipment (USD) -52,000 -31,000 -210,000 -254,000 -197,000 -360,000 -759,000 -8,000
Change in receivables (cash effect) (USD) — — -596,000 -11.6M 11.8M -4.58M 3.23M 986,000
Income taxes paid (cash effect) (USD) -68,000 -61,000 -166,000 0.00 0.00 -509,000 -1.2M -2.39M
Share-based compensation (USD) 1.31M 6.96M 18.8M 34.2M 32.3M 41.1M 49.5M 55.7M
Operating cash flow before change in receivables (USD) — — -82.7M -94.5M -200M -210M -379M -408M
Free cash flow (OCF - PPE - intangibles) (USD) -28.6M -53.4M -83.5M -106M -188M -215M -377M -407M
Income detail
Research and development expense (USD) 25.7M 47.9M 68.6M 102M 160M 213M 361M 457M
↳ 5y CAGR +52.6% +49.7% +46.1%
Total comprehensive income (USD) -28.4M -66.8M -108M -156M -211M -258M -414M -506M
Comprehensive income to owners (USD) -28.4M -66.8M -108M -156M -211M -258M -414M -506M
Reported Jun 29, 2020 Aug 12, 2020 Jun 8, 2022 Jun 8, 2022 May 29, 2024 May 29, 2024 May 29, 2025 May 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Immunovant, Inc. — Results of Operations and Financial Condition Bull 6 Bear 0 Clinical/regulatory

On November 9, 2026, Immunovant, Inc. (“the Company”) issued a press release announcing its financial results for its fiscal second quarter and six months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Roivant 2Q 2026 Earnings Call Bull 0 Bear 0 Not a release

October 21, 2026 7:00 am EDT Download as PDF

DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.

To access the Roivant conference call by phone, please register online using this registration link . The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar . The archived webcast will be available on Immunovant’s website after the conference call.

About Immunovant 

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com . 

Prompts

Immunovant, Inc. (ticker IMVT), listed in United States.

Company History

Date Change Detail
Oct 31, 2019 Renamed HEALTH SCIENCES ACQUISITIONS CORP → IMMUNOVANT, INC.

ETFs Holding Immunovant, Inc.

ETF Weight in ETF Shares Market value As of
FTKI 0.70% 5,337 $ 177.615K Nov 16, 2026
ESSC 0.34% 3,180 $ 122.812K Jul 31, 2026
FSEG 0.23% 340 $ 13.1K Jun 30, 2026
VFMO 0.12% 55,597 $ 2.269M Aug 31, 2026
RESM 0.10% 94 $ 3,621.82 Jun 30, 2026
TMED 0.10% 580 $ 22.347K Jun 30, 2026
TMSL 0.07% 48,117 $ 1.854M Jun 30, 2026
AVIE 0.05% 245 $ 8,153.60 Nov 16, 2026
FESM 0.03% 46,166 $ 1.779M Jun 30, 2026
MKTN short -0.03% -706 $ -27.202K Jun 30, 2026
MSSM 0.02% 3,474 $ 141.809K Aug 31, 2026
DFAS 0.00% 18 $ 630.90 Nov 12, 2026
AVLC 0.00% 242 $ 8,053.76 Nov 16, 2026
NTRL short 0.00% -4,053 $ 0.00 Nov 16, 2026